The Latest Breaking News from FDA

At the heart of the latest battle over abortion access is a federal judge’s ruling that cites concern about the mental health of women who choose to end their pregnancies.

Mifepristone will remain on the market, but approved only for use up to seven weeks of pregnancy, versus 10 weeks, and it cannot be prescribed by telehealth or mailed, which were already illegal in Texas.

The chiefs of more than 400 pharmaceutical companies signed a scathing letter this week blasting federal Judge Matthew Kacsmaryk’s ruling that the Food and Drug Administration had overstepped its authority in approving the abortion-inducing drug mifepristone. The letter was more than justified and, while harshly worded, accurately recounted Kacsmaryk’s abysmal…

Mark my words: Contraception is the next front in the war on women. And we can't say we haven't been warned.

A federal appeals court has preserved access to an abortion drug for now but under tighter rules that would allow the drug only to be dispensed up to seven weeks, not 10, and not by mail.

A federal appeals court has preserved access to an abortion drug for now but under tighter rules that would allow the drug only to be dispensed up to seven weeks, not 10, and not by mail

Three women share their honest experiences taking the controversial diabetes drug.

The ruling means mifepristone is still available in the U.S., but with several strict limitations.

Federal prosecutors have launched a criminal investigation into the Anterior Growth Guidance Appliance, or “AGGA” dental device, following a recent KFF Health News-CBS News investigation, according to a motion filed in federal court.